title: Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.
abstract: Sunitinib (SU11248) is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vascular endothelial growth factor (VEGF) receptors 1, 2, 3, and platelet-derived growth factor receptors alpha (PDGFRA) and beta (PDGFRB). Because angiogenesis is necessary for the growth and metastasis of solid tumours, and VEGF is believed to have a pivotal role in that process, SUNITINIB treatment may have broad-spectrum clinical utility. In the present article, we discuss the biologic and clinical rationales that have recently led the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group to initiate four phase ii trials testing this agent in the following four different tumour types: relapsed diffuse large cell lymphoma, malignant pleural mesothelioma, locally advanced or metastatic cervical cancer and recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
authors: Division of Hematology, Odette Cancer Center, Toronto, Ontario.
authors: R
authors: R
authors: Buckstein
authors: R M
authors: RM
authors: Meyer
authors: L
authors: L
authors: Seymour
authors: J
authors: J
authors: Biagi
authors: H
authors: H
authors: Mackay
authors: S
authors: S
authors: Laurie
authors: E
authors: E
authors: Eisenhauer
references: J Pharmacol Exp Ther. 2005 Dec;315(3):971-9
references: 16002463
references: Lancet. 2006 Oct 14;368(9544):1329-38
references: 17046465
references: Gynecol Oncol. 2002 Jun;85(3):469-75
references: 12051876
references: Leuk Lymphoma. 2005 Sep;46(9):1345-51
references: 16109613
references: Clin Exp Metastasis. 2004;21(2):107-18
references: 15168728
references: J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93
references: 12359857
references: J Clin Oncol. 1991 Mar;9(3):389-93
references: 1999708
references: Med Oncol. 2001;18(4):269-75
references: 11918453
references: Br J Haematol. 1999 Aug;106(2):504-9
references: 10460612
references: Ann Oncol. 2004 Feb;15(2):257-60
references: 14760119
references: J Pathol. 2001 Apr;193(4):468-75
references: 11276005
references: J Clin Oncol. 1996 Mar;14(3):792-5
references: 8622025
references: Blood. 2001 Jun 1;97(11):3658-61
references: 11369666
references: Science. 2006 Sep 22;313(5794):1785-7
references: 16990548
references: Curr Opin Oncol. 2005 Nov;17(6):611-6
references: 16224242
references: Clin Cancer Res. 2003 Jan;9(1):377-82
references: 12538491
references: Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):805-7
references: 8456884
references: J Clin Oncol. 1985 Aug;3(8):1079-85
references: 3894589
references: Int J Oncol. 2000 Apr;16(4):777-82
references: 10717248
references: Am J Epidemiol. 2004 Jan 15;159(2):107-12
references: 14718210
references: Cancer Res. 2001 Jun 1;61(11):4341-4
references: 11389057
references: Cancer Metastasis Rev. 2000;19(1-2):167-72
references: 11191056
references: Ann Oncol. 2005;16 Suppl 8:viii13-viii19
references: 16239232
references: Blood. 2005 Feb 1;105(3):986-93
references: 15459012
references: Blood. 2004 Nov 1;104(9):2893-902
references: 15238424
references: J Clin Oncol. 2005 Jul 20;23(21):4626-33
references: 15911865
references: N Engl J Med. 1987 Jun 11;316(24):1493-8
references: 3295541
references: Radiother Oncol. 1995 May;35(2):107-17
references: 7569018
references: Lancet. 2003 Jun 21;361(9375):2099-106
references: 12826431
references: Exp Hematol. 2000 Sep;28(9):993-1000
references: 11008011
references: Bone Marrow Transplant. 2003 Oct;32(7):673-9
references: 13130314
references: Br J Cancer. 1999 Sep;81(1):54-61
references: 10487612
references: Gynecol Oncol. 2005 Mar;96(3):902-5
references: 15721449
references: Eur J Cancer. 1997 Mar;33(3):500-2
references: 9155539
references: Oncogene. 2005 Jan 13;24(3):489-501
references: 15516973
references: Virchows Arch. 1999 Jul;435(1):8-12
references: 10431840
references: N Engl J Med. 2007 Jan 11;356(2):115-24
references: 17215529
references: J Clin Oncol. 2007 Nov 20;25(33):5165-71
references: 18024863
references: Cancer Cell. 2005 Jan;7(1):101-11
references: 15652753
references: Mol Pathol. 2002 Dec;55(6):348-59
references: 12456770
references: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references: 15661684
references: Blood. 2000 Jul 1;96(1):282-7
references: 10891463
references: Int J Cancer. 2003 May 1;104(5):603-10
references: 12594815
references: Leuk Lymphoma. 2009 May;50(5):728-35
references: 19373598
references: Semin Oncol. 1994 Feb;21(1):54-62
references: 8310310
references: Adv Exp Med Biol. 2003;522:83-97
references: 12674213
references: N Engl J Med. 1993 Apr 8;328(14):1002-6
references: 7680764
references: Blood. 1992 Oct 15;80(8):2142-8
references: 1356515
references: J Clin Oncol. 2007 Mar 1;25(7):884-96
references: 17327610
references: Semin Oncol. 2002 Apr;29(2 Suppl 6):18-22
references: 12040530
references: Cancer. 2005 Feb 15;103(4):724-30
references: 15637689
references: Clin Cancer Res. 2006 Sep 1;12(17):5190-8
references: 16951238
references: Gynecol Oncol. 2001 May;81(2):213-5
references: 11354055
references: Nat Med. 2003 Jun;9(6):653-60
references: 12778163
references: Br J Cancer. 1997;76(9):1221-7
references: 9365173